{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:59:06Z","timestamp":1787457546896,"version":"build-2736575974"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T00:00:00Z","timestamp":1597190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conventional first-line combination therapy for ovarian cancer comprises 6 cycles of adjuvant or neoadjuvant carboplatin (AUC5-6) with paclitaxel (175 mg\/m2) every 3\u2009weeks (PC-3W). Weekly scheduling of paclitaxel may maximize its antiangiogenic effect and reduce adverse effects. We compared the efficacy and safety of PC-3W with a modified protocol of weekly paclitaxel 80 mg\/m2 and weekly carboplatin AUC2 administered on days 1, 8, and 15 in a 28-day cycle (i.e., with 1 week off-treatment [PC-W]).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Medical records of consecutive patients treated between 2000 and 2018 were reviewed; 707 patients were analyzed for demographic and clinical characteristics, effectiveness and toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>PC-3W was administered to 402 patients (median age, 60.5\u2009years) and PC-W to 305 patients (median age, 62.5\u2009years). Most patients (91.4%) were diagnosed at stage III\u2013IV. Notwithstanding a higher proportion of residual disease and older patients in the PC-W group, median progression-free survival was 21.4 months and 13.2 months for PC-W and PC-3W, respectively; median overall survival was 75.2 and 54.0 months for PC-W and PC-3W, respectively. Cox proportional hazards model indicated improved survival for patients treated with PC-W (hazard ratio, 0.54). Similar results were observed for older patients diagnosed at \u226575\u2009years. PC-W demonstrated a better safety profile, with lower incidence of neuropathy, neutropenia, and alopecia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PC-W is as active and better tolerated than the standard PC-3W regimen. PC-W may serve as an alternative option for elderly or frail patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Practice<\/jats:title>\n                    <jats:p>Weekly scheduling of paclitaxel 80 mg\/m2 and carboplatin AUC2, administered on days 1, 8, and 15 in a 28-day cycle (PC-W) for first-line therapy for advanced ovarian cancer, is as active and better tolerated than the standard regimen of carboplatin and paclitaxel (175 mg\/m2) every 3\u2009weeks (PC-3W). It is possible that the weekly holiday on day 21 in the PC-W regimen may ensure better completion rates (which may result in treatment delays for toxicity in PC-3W). The results of this retrospective analysis highlight the weekly regimen as a valid treatment option, especially for elderly patients and those with significant comorbidities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1634\/theoncologist.2020-0196","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T07:28:32Z","timestamp":1594625312000},"page":"30-39","source":"Crossref","is-referenced-by-count":16,"title":["Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer"],"prefix":"10.1093","volume":"26","author":[{"given":"Tamar","family":"Safra","sequence":"first","affiliation":[{"name":"Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barliz","family":"Waissengrin","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talya","family":"Levy","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"},{"name":"Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Wolfson Medical Center, Holon, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellie","family":"Leidner","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotem","family":"Merose","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Matceyevsky","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Grisaru","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Laskov","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadav","family":"Mishaan","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rotem","family":"Shayzaf","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ido","family":"Wolf","sequence":"additional","affiliation":[{"name":"Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,8,12]]},"reference":[{"key":"2021122511544004800_onco13449-bib-0001","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"2021122511544004800_onco13449-bib-0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2021122511544004800_onco13449-bib-0003","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021122511544004800_onco13449-bib-0004","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122511544004800_onco13449-bib-0005","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/IGC.0b013e31821ce75d","article-title":"First-line therapy in ovarian cancer trials","volume":"21","author":"Thigpen","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"2021122511544004800_onco13449-bib-0006","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122511544004800_onco13449-bib-0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122511544004800_onco13449-bib-0008","doi-asserted-by":"crossref","first-page":"9552","DOI":"10.1073\/pnas.90.20.9552","article-title":"Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations","volume":"90","author":"Jordan","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021122511544004800_onco13449-bib-0009","first-page":"816","article-title":"Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death","volume":"56","author":"Jordan","year":"1996","journal-title":"Cancer Res"},{"key":"2021122511544004800_onco13449-bib-0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1634\/theoncologist.6-suppl_3-30","article-title":"Theoretical concepts and the emerging role of taxanes in adjuvant therapy","volume":"6","author":"Norton","year":"2001","journal-title":"The Oncologist"},{"key":"2021122511544004800_onco13449-bib-0011","first-page":"3620","article-title":"Mechanisms of Taxol-induced cell death are concentration dependent","volume":"58","author":"Torres","year":"1998","journal-title":"Cancer Res"},{"key":"2021122511544004800_onco13449-bib-0012","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11523-006-0012-7","article-title":"Effect of paclitaxel on vascular endothelial growth factor (VEGF) and interleukin (IL)-8 in serum of patients with recurrent ovarian cancer: a comparison of weekly vs triweekly regimens","volume":"1","author":"Saito","year":"2006","journal-title":"Target Oncol"},{"key":"2021122511544004800_onco13449-bib-0013","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122511544004800_onco13449-bib-0014","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122511544004800_onco13449-bib-0015","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3\u2009weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"key":"2021122511544004800_onco13449-bib-0016","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3\u2009weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122511544004800_onco13449-bib-0017","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.04.008","article-title":"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma","volume":"114","author":"Safra","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"suppl 5","key":"2021122511544004800_onco13449-bib-0018","first-page":"v605","article-title":"ICON8: A GCIG Phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian\/ fallopian tube\/ primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) Analysis","volume":"28","author":"Clamp","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122511544004800_onco13449-bib-0019","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.2217\/pgs.14.127","article-title":"SNPs and taxane toxicity in breast cancer patients","volume":"15","author":"Bos\u00f3","year":"2014","journal-title":"Pharmacogenomics"},{"key":"2021122511544004800_onco13449-bib-0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.2217\/pgs.13.90","article-title":"Germline pharmacogenetics of paclitaxel for cancer treatment","volume":"14","author":"Hertz","year":"2013","journal-title":"Pharmacogenomics"},{"key":"2021122511544004800_onco13449-bib-0021","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/S0140-6736(00)03167-6","article-title":"Pharmacogenetics and adverse drug reactions","volume":"356","author":"Meyer","year":"2000","journal-title":"Lancet"},{"key":"2021122511544004800_onco13449-bib-0022","doi-asserted-by":"crossref","first-page":"58709","DOI":"10.18632\/oncotarget.11094","article-title":"Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis","volume":"7","author":"Marchetti","year":"2016","journal-title":"Oncotarget"},{"key":"2021122511544004800_onco13449-bib-0023","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","article-title":"Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma","volume":"96","author":"Vasey","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122511544004800_onco13449-bib-0024","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fphar.2017.00086","article-title":"Long-term effects, pathophysiological mechanisms, and risk factors of chemotherapy-induced peripheral neuropathies: A comprehensive literature review","volume":"8","author":"Kerckhove","year":"2017","journal-title":"Front Pharmacol"},{"key":"2021122511544004800_onco13449-bib-0025","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-016-3939-0","article-title":"Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: Prevalence, risk factors, and fall risk","volume":"159","author":"Bao","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"2021122511544004800_onco13449-bib-0026","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ijgo.13137","article-title":"Chemotherapy-induced peripheral neuropathy among patients with ovarian cancer","volume":"149","author":"Jin","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"key":"2021122511544004800_onco13449-bib-0027","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122511544004800_onco13449-bib-0028","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00280-013-2173-2","article-title":"A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma","volume":"72","author":"Abaid","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122511544004800_onco13449-bib-0029","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00280-016-3187-3","article-title":"Dose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas","volume":"78","author":"Ebata","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2021122511544004800_onco13449-bib-0030","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2014.07.015","article-title":"Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel\/platinum induction therapy followed by standard or extended three-weekly paclitaxel\/platinum in European patients with advanced epithelial ovarian cancer","volume":"50","author":"van der Burg","year":"2014","journal-title":"Eur J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1634%2Ftheoncologist.2020-0196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2020-0196","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2020-0196","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/1\/30\/41923890\/oncolo_26_1_30.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/1\/30\/41923890\/oncolo_26_1_30.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T06:56:47Z","timestamp":1640415407000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/1\/30\/6445330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,8,12]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2020-0196","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2020,8,12]]}}}